임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 3상모집 중단 (진행 중)· Advanced Clear Cell Renal Cell CarcinomaA Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Heterozygous Familial HypercholesterolaemiaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Cardiovascular DiseaseA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· NMOSDEfficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD
협력: 아스트라제네카
- 3상모집 중단 (진행 중)· Locally Advanced or Metastatic Breast CancerA Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Advanced or Recurrent Endometrial CancerA Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Chronic Rhinosinusitis With Nasal PolypsA Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Non-small Cell Lung CancerA Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Breast CancerCapivasertib+Fulvestrant asTreatment for Locally Advanced(Inoperable) or Metastatic HR+/HER2- Breast Cancer in Chinese Patients
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Cutaneous Lupus ErythematosusA Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Chronic Kidney Disease and HypertensionA Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Severe Eosinophilic AsthmaSTEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Biliary Tract CancerRilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Transthyretin Amyloid CardiomyopathyEPIC-ATTR: A Study to Evaluate the Effect of Eplontersen on the Transthyretin Reduction and Long-term Safety in Chinese Subjects With Transthyretin Amyloid Cardiomyopathy
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Metastatic Castration-Sensitive Prostate CancerSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Unresectable Pleural MesotheliomaMEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Systemic SclerosisDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Chronic Kidney Disease With High ProteinuriaStudy to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Metastatic Non-small Cell Lung CancerA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Chronic Obstructive Pulmonary Disease (COPD)Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Biliary Tract CancerDurvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Non-Muscle- Invasive Bladder CancerBCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Advanced Hepatocellular CarcinomaDurvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· CancerRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Hepatocellular CarcinomaDurvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Metastatic Non Small Cell Lung CancerDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
협력: 아스트라제네카, 머크(MSD)
- 3상모집 중단 (진행 중)· Eosinophilic EsophagitisEfficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
리드: 아스트라제네카 · 협력: 암젠
- 3상모집 중단 (진행 중)· Advanced or Metastatic Non-Small Cell Lung CancerA Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Intracranial ArteriosclerosisComparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
협력: 아스트라제네카
- 3상모집 중단 (진행 중)· Erosive EsophagitisEndoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to 11 Years Old With Erosive Esophagitis.
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Hepatocellular CarcinomaEvaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Prostate CancerStudy of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Metastatic Non Small Cell Lung CancerStudy of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
협력: 아스트라제네카, 머크(MSD)
- 3상모집 중단 (진행 중)· Non-Small Cell Lung CancerA Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Lupus NephritisPhase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Neurofibromatosis 1Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform Neurofibromas
리드: 아스트라제네카 · 협력: 머크(MSD)
- 3상모집 중단 (진행 중)· Papillary Renal Cell CarcinomaSavolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Locally Advanced or Metastatic Non-Small Cell Lung CancerA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Breast NeoplasmsTrastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Breast CancerA Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Non-small Cell Lung CancerA Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Muscle Invasive Bladder CancerTreatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· ER-Positive HER2-Negative Breast CancerPhase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Metastatic Castration-resistant Prostate CancerStudy on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)
리드: 아스트라제네카 · 협력: 머크(MSD)
- 3상모집 중단 (진행 중)· Breast CancerA Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Systemic Lupus ErythematosusSubcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
리드: 아스트라제네카
- 3상모집 중단 (진행 중)· Gastric Cancer, AdenocarcinomaTrastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
협력: 아스트라제네카
- 3상모집 중단 (진행 중)· Breast Cancer; HER2-positive; MetastaticTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
리드: 아스트라제네카
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.